Search publications
19 results found
-
Decision on objection against fine on Leadiant for excessive price of prescription drug CDCA
On 1 July 2021, the Netherlands Authority for Consumers and Markets (ACM) imposed a fine on Leadiant for charging an excessive price for its prescription drug CDCA-Leadiant, thereby abusing its dominant position from June 2017 through December 2019. … -
ACM: If practices are full, GPs that are looking for a spot for switching patients do not violate competition rules
Following an investigation into reports filed by patients that were not able to switch to certain general practitioners (GPs), the Netherlands Authority for Consumers and Markets (ACM) announces that, if there is a shortage of GPs and GP practices are … -
Lack of clarity regarding contracted health care as well as emphasis on price pose risks for insured
When deciding to switch or not to switch health insurance policies, more than one in three insured were not aware that negotiations over reimbursable health care were still ongoing between health care providers and health insurers. In addition, 70 percent … -
ACM: anti-competitive risks for some medical devices
The Netherlands Authority for Consumers and Markets (ACM) sees anticompetitive risks in some markets for medical devices. With regard to high-technological medical devices in particular, there are relatively few providers, and new providers face high … -
ACM guidelines regarding the competition rules for the health care IT market have been well received
The guidelines called ‘Well-functioning markets for health care IT’ clarifies the application of the competition rules for improving the functioning of the market for health care IT systems. In the summer of 2022, the Netherlands Authority for Consumers … -
ACM: elderly care provider Omring meets conditions attached to acquisition of rival provider Vrijwaard
Elderly care provider Omring has received clearance needed to complete the acquisition of rival provider Vrijwaard in the northern Dutch city of Den Helder. With the sale of the care activities in three nursing homes, the providers have met the conditions … -
ACM closes investigation into drug manufacturer AbbVie, competitors get more room now
Drug manufacturer AbbVie has stated that it will not force hospitals to purchase exclusively or to a large extent from AbbVie through discount schemes (or rebate programs). AbbVie has made these assurances following an investigation conducted by the … -
ACM extends its investigation into orphan drug CDCA-Leadiant
The Netherlands Authority for Consumers and Markets (ACM) extends its investigation into the orphan drug CDCA manufactured by Leadiant. The investigation focuses on the question whether the manufacturer abuses a dominant position in the pricing of the … -
Further investigation needed into merger of three geriatric-care providers in the south of the Netherlands
Dutch health care providers Stichting Schakelring, Stichting De Riethorst Stromenland and Stichting Volckaert wish to merge. These care providers offer nursing-home care and other forms of geriatric care in the south of the Netherlands (more specifically, … -
Evaluation of ACM’s Guidelines on the collective procurement of prescription drugs
In 2016, the Netherlands Authority for Consumers and Markets (ACM) published the Guidelines on the collective procurement of prescription drugs. ACM drew up these guidelines to give hospitals and health insurers more clarity about the room that the …